These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
464 related articles for article (PubMed ID: 34660285)
1. Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With Tang X; Li Y; Yan WF; Qian WL; Pang T; Gong YL; Yang ZG Front Oncol; 2021; 11():719919. PubMed ID: 34660285 [TBL] [Abstract][Full Text] [Related]
2. Can CT Radiomics Detect Acquired T790M Mutation and Predict Prognosis in Advanced Lung Adenocarcinoma With Progression After First- or Second-Generation EGFR TKIs? Yang X; Fang C; Li C; Gong M; Yi X; Lin H; Li K; Yu X Front Oncol; 2022; 12():904983. PubMed ID: 35875167 [TBL] [Abstract][Full Text] [Related]
3. CT Radiomics Predict EGFR-T790M Resistance Mutation in Advanced Non-Small Cell Lung Cancer Patients After Progression on First-line EGFR-TKI. Tang X; Li Y; Shen LT; Yan WF; Qian WL; Yang ZG Acad Radiol; 2023 Nov; 30(11):2574-2587. PubMed ID: 36941156 [TBL] [Abstract][Full Text] [Related]
4. A Radiomics-clinical Nomogram based on CT Radiomics to Predict Acquired T790M Mutation Status in Non-small Cell Lung Cancer Patients. Xiong W; Yu X; Zhou T; Huang H; Zhao Z; Wang T Curr Med Imaging; 2024 Mar; ():. PubMed ID: 38523520 [TBL] [Abstract][Full Text] [Related]
5. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients. Tang YJ; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291877 [TBL] [Abstract][Full Text] [Related]
6. Radiomics of metastatic brain tumor as a predictive image biomarker of progression-free survival in patients with non-small-cell lung cancer with brain metastasis receiving tyrosine kinase inhibitors. Wang TW; Chao HS; Chiu HY; Lu CF; Liao CY; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT Transl Oncol; 2024 Jan; 39():101826. PubMed ID: 37984256 [TBL] [Abstract][Full Text] [Related]
7. Enhancing intracranial efficacy prediction of osimertinib in non-small cell lung cancer: a novel approach through brain MRI radiomics. Tang X; Li Y; Qian WL; Han PL; Yan WF; Yang ZG Front Neurol; 2024; 15():1399983. PubMed ID: 39281414 [TBL] [Abstract][Full Text] [Related]
8. PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs. Yang L; Xu P; Li M; Wang M; Peng M; Zhang Y; Wu T; Chu W; Wang K; Meng H; Zhang L Front Oncol; 2022; 12():894323. PubMed ID: 35800046 [TBL] [Abstract][Full Text] [Related]
9. Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance. Ma J; Tan SH; Yin DXC; Tran NTA; Tan GS; Lai GGY; Ang MK; Kanesvaran R; Jain A; Rajasekaran T; Tan EH; Lim TKH; Tan DS; Lim DW; Ng QS; Tan WL Transl Lung Cancer Res; 2023 Apr; 12(4):742-753. PubMed ID: 37197627 [TBL] [Abstract][Full Text] [Related]
10. Predicting EGFR mutation subtypes in lung adenocarcinoma using Liu Q; Sun D; Li N; Kim J; Feng D; Huang G; Wang L; Song S Transl Lung Cancer Res; 2020 Jun; 9(3):549-562. PubMed ID: 32676319 [TBL] [Abstract][Full Text] [Related]
11. CT-based nomogram for early identification of T790M resistance in metastatic non-small cell lung cancer before first-line epidermal growth factor receptor-tyrosine kinase inhibitors therapy. Li Y; Lv X; Wang Y; Xu Z; Lv Y; Hou D Eur Radiol Exp; 2023 Nov; 7(1):64. PubMed ID: 37914925 [TBL] [Abstract][Full Text] [Related]
12. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885 [TBL] [Abstract][Full Text] [Related]
13. A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lu CF; Liao CY; Chao HS; Chiu HY; Wang TW; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT Cancer Imaging; 2023 Jan; 23(1):9. PubMed ID: 36670497 [TBL] [Abstract][Full Text] [Related]
14. Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring Chen CH; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE Anticancer Res; 2022 Apr; 42(4):2145-2157. PubMed ID: 35347039 [TBL] [Abstract][Full Text] [Related]
15. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer. Walia M; Singhal MK; Kamle MS Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193 [TBL] [Abstract][Full Text] [Related]
16. CT-Based Radiomic Signature as a Prognostic Factor in Stage IV Li H; Zhang R; Wang S; Fang M; Zhu Y; Hu Z; Dong D; Shi J; Tian J Front Oncol; 2020; 10():57. PubMed ID: 32133282 [No Abstract] [Full Text] [Related]
17. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms. Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618 [TBL] [Abstract][Full Text] [Related]
18. Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer. Cucchiara F; Del Re M; Valleggi S; Romei C; Petrini I; Lucchesi M; Crucitta S; Rofi E; De Liperi A; Chella A; Russo A; Danesi R Front Oncol; 2020; 10():593831. PubMed ID: 33489892 [TBL] [Abstract][Full Text] [Related]
19. Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC. Lu J; Ji X; Liu X; Jiang Y; Li G; Fang P; Li W; Zuo A; Guo Z; Yang S; Ji Y; Lu D Sci Rep; 2024 Jan; 14(1):446. PubMed ID: 38172228 [TBL] [Abstract][Full Text] [Related]